Amgen (AMGN) Deep Dive: The “MariTide” Gamble & The Horizon Debt Burden Amgen (AMGN) stands at a critical crossroads in 2025. The narrative has shifted from a safe dividend haven to a high-stakes growth play in the obesity market. At UsFinanceNow, we analyze whether the hype around MariTide (AMG 133) is justified and how the … Read more
Procter & Gamble (PG) Analysis: Why the Stock is Down & Is It a Buy at $140s? The consumer staples giant is bleeding. As we head into late 2025, Procter & Gamble (PG) is trading dangerously close to its 52-week lows. For investors used to stability, this correction is alarming. At UsFinanceNow, we analyzed the … Read more
Tesla (TSLA) Q3 2025 Deep Dive: The Dangerous Game of Margins vs. Growth Tesla’s Q3 2025 earnings report is one of the most polarizing in recent history. On the surface, it looks like a victory lap: record deliveries and record revenue. But dig deeper into the financial statements, and you’ll find a company sacrificing short-term … Read more